ABSTRACT
INTRODUCTION
Liver glucose overproduction, particularly gluconeogenesis is a key element of hyperglycemia in prediabetes and type 2 diabetes (Monnier et al. 2008) . For this reason, metformin has become a mainstay in the modest therapeutic armamentarium to prevent the liver glucose overproduction (Viollet et al. 2009 ) and represents the first line oral treatment for patients who are unable to achieve glycemic control with diet and exercise (ADA 2010 ). However, metformin shows several adverse effects, including nausea, vomiting, diarrhea, flatulence (Florez et al. 2010) and is contraindicated in conditions that could increase the risk of lactic acidosis, including kidney disorders, lung disease and liver disease (Friesecke et al. 2010) . Considering that except metformin there are only a few pharmacological alternatives to reduce the liver glucose overproduction (ADA 2010; Tomas et al. 2010) , the development of new drugs, which influences this metabolic process must be investigated. In this context, the anti-TNF-alpha monoclonal antibody infliximab showed beneficial effects not only for the diseases such as rheumatoid arthritis, Crohn's disease, and psoriatic arthritis (Karampetsou et al. 2010 ) but also for type 2 diabetic patients (Ursini 2009; Ursini et al. 2010; Yazdani-Biuki et al. 2006) . The mechanism by which infliximab improves the glycemic control involves an inactivation of TNF-alpha activity (Yazdani-Biuki et al. 2006; Ursini 2009 ). Moreover, a previous study showed that the treatment with infliximab improved the signal transduction through the insulin receptors in liver in an animal model of diet-induced obesity and diabetes (Araújo et al. 2007 ). However, the effect of infliximab on liver glucose overproduction was not investigated. Therefore, in this study an animal model of dietinduced liver glucose overproduction was used to determine the effect of infliximab on liver gluconeogenesis from L-alanine. The reason of using this amino acid was based on the following facts that L-alanine was the main gluconeogenic substrate and its conversion to glucose used all the steps of the gluconeogenic pathway (OliveiraYamashita et al. 2009 ).
MATERIALS AND METHODS
L-alanine was obtained from ICN Biochemichals (Costa Mesa, CA, USA). Infliximab was purchased from Centocor (Horsham, PA, USA). All other reagents were of the highest purity obtainable. The mice (30-35 g) were maintained with constant temperature (23°C) and automatically controlled photoperiod (12-h light/12-h dark). The high fat diet was obtained by the addition of pork fat (Sadia®) in the regular rodent chow (Nuvital®) increasing the lipid composition from 4.5 to 48%. The control group received regular rodent chow (Nuvital®). Mice were treated either with a standard diet (SD group) or with a high fat diet (HFD group) during two or four weeks. Since fasting hyperglycemia was well established two weeks after the introduction of the HFD diet (not shown), this period of treatment was used in the next set of experiments. For this purpose, HFD group were randomly divided and treated either with saline (100 µl/dose, ip, twice a day) or with infliximab (10 µg in 100 µl saline per dose, ip, twice a day). Moreover, SD group also received saline (100 µl/dose, ip, twice a day). The daily dose of infliximab (0.5 mg/kg) and schedule of administration (9:00 a.m. and 5:00 p.m.) were based on a previous study (Araújo et al. 2007 ). The treatment with infliximab or saline started on the first day of the introduction of the HFD and was maintained until the day before the experiments when the animals were food deprived from 5:00 p.m. All the experiments were performed in 15 h fasted mice (5:00 p.m. -8:00 a.m.) when the mice were anesthetized with ip thiopental (120 mg/kg). After laparotomy, blood was collected from the cava vein for glucose determination (Bergmeyer and Bernt 1974) and the liver perfusion was started immediately. The in situ liver perfusion technique was done as previously described (Galende et al. 2009; Oliveira-Yamashita et al. 2009 ). Figure 1 showed a demonstrative experiment in which after a preinfusion period (10 min), L-alanine was infused during 60 min, followed by a post-infusion period (10 min without L-alanine) to allow the return of basal glucose production values of the pre-infusion period. The samples of the effluent perfusion fluid were collected each 5 min and the glucose concentration was measured. The difference between the glucose production during and before L-alanine infusion represented the glucose production from gluconeogenesis. The areas under the curves (AUC) of the infusion period with Lalanine were expressed as µmol/g. In addition to glucose (Bergmeyer and Bernt 1974) , the production of pyruvate (Czok and Lamprecht 1974) , urea (Gutmann and Bergmeyer 1974) and L-lactate (Gutmann and Wahlefeld 1974) in the liver were also evaluated. At the end of the experiment, the liver was removed and weighed to allow precise metabolic calculations and the correction of flow rates. The program GraphPad Prism (version 6.0) was used to calculate the AUC. Data were analyzed statistically by the unpaired Student's t-test. A 95% level of confidence (p < 0.05) was accepted for all the comparisons. Results are reported as means + standard deviation (SD). 
RESULTS
The treatment with infliximab during two weeks did not change caloric intake and body weight (Results not shown).
Since in situ perfused livers reflected the in vivo conditions of the animal immediately before the liver isolation (Galende et al. 2009; OliveiraYamashita et al., 2009 ) and considering that mice treated with a HFD were a suitable experimental model to induce the liver glucose overproduction (Tomas et al. 2010; Wu et al. 2010) , this experimental approach was used. As showed by Table 1 , the treatment with infliximab prevented the glucose overproduction during the infusion of L-alanine in the liver from HFD mice (p<0.05: HFD + Infliximab vs. HFD + Saline). This result could be attributed, partly at least, to the decreased catabolism of L-alanine, since the L-lactate production from this amino acid was also decreased (p<0.05: HFD + Infliximab vs. HFD + Saline) and urea production showed a clear tendency to decrease (p>0.05: HFD + Infliximab vs. HFD + Saline). Moreover, since pyruvate production from L-alanine showed clear tendency to be higher (p>0.05: HFD + Infliximab vs. HFD + Saline), the possibility of a lower entrance of pyruvate in the gluconeogenic pathway must be considered. 
DISCUSSION
This is the first evidence showing that infliximab could prevent the liver glucose overproduction. The mechanism involved in this effect remained to be investigated. However, the inactivation of TNFalpha might play a key role in this process (Ursini et al., 2010; Yazdani-Biuki et al. 2006) . In fact, it is well established that TNF-alpha from adipocytes disrupts the insulin signaling machinery by activating serine kinases that targets the proteins such as the insulin receptor (IR)/ IR substrate-1(IRS-1), and IR substrate-2 (IRS-2), producing insulin resistance (Lorenzo et al. 2008) . Moreover, the mechanism by which infliximab promotes the inhibition of gluconeogenesis and reduction of fasting glycemia certainly involves improvement in insulin signal transduction through IR/ IRS-1 and IRS-2/ Akt/ forkhead box protein O1 (FOXO1) pathway (Araújo et al. 2007) . The values of glycemia for SD group, HFD group treated with saline and HFD group treated with infliximab were 66.1 + 15.5, 93.4 + 25.9 and 66.8 + 15.5, respectively. Therefore, consistent with the results of liver glucose production from Lalanine, HFD + infliximab group showed lower glycemia if compared with HFD mice treated with saline (p<0.05: HFD + Infliximab vs. HFD + Saline). It should be noticed that a direct effect of infliximab treatment lowering glycemia was previously demonstrated (Araújo et al. 2007 ). Thus, it could be concluded that this investigation provided additional support for the role of TNFalpha in the pathogenesis of diabetes and suggested that the pharmacological inhibition of TNF-alpha by infliximab could be an attractive approach for the prevention of glucose overproduction related with glucose intolerance and type 2 diabetes. On the other hand, considering that metformin decreases glucose overproduction by a different mechanism and participates in regulating the release of TNF alpha (Labuzek et al. 2010) , the possibility of the combination of these drugs must be considered.
